1. Delayed Pituitary Adenylate Cyclase–Activating Polypeptide Delivery After Brain Stroke Improves Functional Recovery by Inducing M2 Microglia/Macrophage Polarization
- Author
-
Victor May, David Vaudry, Coralie Brifault, Marjorie Gras, Olivier Wurtz, Donovan Liot, Neuroendocrinologie cellulaire et moléculaire, Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), University of Vermont College of Medicine, University of Vermont [Burlington], International Associated laboratory Samuel de Champlain, Institut National de la Recherche Scientifique [Québec] (INRS)-Université de Rouen Normandie (UNIROUEN), Différenciation et communication neuronale et neuroendocrine (DC2N), Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de la Recherche Scientifique [Québec] (INRS)-Université de Rouen Normandie (UNIROUEN), and Normandie Université (NU)-Normandie Université (NU)
- Subjects
Male ,Time Factors ,[SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology ,microglia ,Pharmacology ,[SDV.IMM.II]Life Sciences [q-bio]/Immunology/Innate immunity ,Mice ,Drug Delivery Systems ,MESH: Animals ,Stroke ,Microglia ,Brain ,Cell Polarity ,MESH: Recovery of Function ,stroke ,pituitary adenylate cyclase-activating polypeptide ,MESH: Microglia ,medicine.anatomical_structure ,[SDV.IMM.IA]Life Sciences [q-bio]/Immunology/Adaptive immunology ,medicine.symptom ,Stem cell ,MESH: Stem Cell Transplantation ,MESH: Cell Polarity ,MESH: Injections, Intraventricular ,Cardiology and Cardiovascular Medicine ,Programmed cell death ,Mice, 129 Strain ,MESH: Mice, Transgenic ,MESH: Drug Delivery Systems ,Ischemia ,Adenylate kinase ,Inflammation ,Mice, Transgenic ,Neuroprotection ,MESH: Stroke ,MESH: Brain ,MESH: Mice, 129 Strain ,medicine ,Animals ,MESH: Mice ,Injections, Intraventricular ,Advanced and Specialized Nursing ,business.industry ,Macrophages ,MESH: Pituitary Adenylate Cyclase-Activating Polypeptide ,MESH: Time Factors ,MESH: Macrophages ,Recovery of Function ,medicine.disease ,MESH: Male ,inflammation ,Immunology ,Neurology (clinical) ,business ,Stem Cell Transplantation - Abstract
Background and Purpose— Until now, except thrombolysis, the therapeutical strategies targeting the acute phase of cerebral ischemia have been proven ineffective, and no approach is available to attenuate the delayed cell death mechanisms and the resulting functional deficits in the late phase. Then, we investigated whether a targeted and delayed delivery of pituitary adenylate cyclase–activating polypeptide (PACAP), a peptide known to exert neuroprotective activities, may dampen delayed pathophysiological processes improving functional recovery. Methods— Three days after permanent focal ischemia, PACAP-producing stem cells were transplanted intracerebro ventricularly in nonimmunosuppressed mice. At 7 and 14 days post ischemia, the effects of this stem cell–based targeted delivery of PACAP on functional recovery, volume lesions, and inflammatory processes were analyzed. Results— The delivery of PACAP in the vicinity of the infarct zone 3 days post stroke promotes fast, stable, and efficient functional recovery. This was correlated with a modulation of the postischemic inflammatory response. Transcriptomic and Ingenuity Pathway Analysis–based bioinformatic analyses identified several gene networks, functions, and key transcriptional factors, such as nuclear factor-κB, C/EBP-β, and Notch/RBP-J as PACAP’s potential targets. Such PACAP-dependent immunomodulation was further confirmed by morphometric and phenotypic analyses of microglial cells showing increased number of Arginase-1 + cells in mice treated with PACAP-expressing cells specifically, demonstrating the redirection of the microglial response toward a neuroprotective M2 phenotype. Conclusions— Our results demonstrated that immunomodulatory strategies capable of redirecting the microglial response toward a neuroprotective M2 phenotype in the late phase of brain ischemia could represent attractive options for stroke treatment in a new and unexploited therapeutical window.
- Published
- 2015
- Full Text
- View/download PDF